A Year After 'Liberation Day,' Trump Sets New Drug Tariffs, Adjusts Metals Duties

President Trump ordered 100% tariffs on certain branded pharmaceutical imports (20% if firms only partially relocate; full avoidance if companies both cut U.S. drug prices via deals and move production), with caps of 15% under deals with the EU, Japan, South Korea and Switzerland and a separate US-UK zero-tariff pledge for at least three years; large drugmakers have 120 days (smaller ones 180) to comply. He also changed metals tariffs: commodity steel, aluminum and copper stay at 50% but duties on many metal derivatives were halved to 25%, products with <15% metal content are exempt, and certain metal-intensive industrial/power-grid equipment duties are cut to 15% through 2027; valuation will be based on U.S. sales price. The package is likely sector-moving—raising potential healthcare and manufacturing input costs (industry groups warned) while benefiting domestic metals producers and aiming to restore duties invalidated by the Supreme Court.

Analysis

The policy pivot creates an effective protection layer for domestic metals and upstream suppliers by changing how import bills are calculated and which products are carved out. Expect U.S. mills and integrated processors to capture more of the value chain — not just raw metal — which should drive EBITDA margin expansion for domestic producers over the next 3–12 months as import pricing becomes less competitive and inventory restocking shifts onshore.

For branded pharmaceuticals the implicit regulatory pressure to localize production and accept price concessions rewrites capital allocation for global pharma groups: expect a multi-year rerating of CDMOs, API makers and engineering firms with U.S. footprints. Smaller, specialized U.S. contract manufacturers and industrial contractors are the natural shortlists for outsized volume gains; conversely, large foreign-origin brand manufacturers face higher effective cost of doing business into the U.S. market and more volatile earnings visibility.

Downstream second-order effects matter: reduced tariff complexity and lower applied rates on heavy industrial equipment materially lower capex uncertainty for grid, data-center and renewables builds — that should accelerate near-term orders for transformers, switchgear and cabling while keeping long-term input inflation elevated. Conversely, import-dependent OEMs with tight margins and limited pricing power will see throughput and inventory frictions, increasing dispersion across industrials and consumer durables in the coming quarters.

Tail risks are legal and geopolitical: trade partners could retaliate or litigate, and implementation guidance will drive who actually benefits. Watch administrative rulemaking and customs enforcement clarifications as high-probability catalysts over weeks to months; a court reversal or major trade retaliation would compress the upside for domestic winners quickly, while a smooth implementation would reinforce the re-shoring narrative over years.

Key Decisions for Investors

• Long NUE (Nucor) stock or a 6–12 month call spread (buy 1 call, sell higher strike) — thesis: margin expansion from constrained import competition and higher domestic pricing. Risk: demand shock/industrial slowdown. Target: 25–40% upside if steel spreads re-price; risk defined by premium paid.
• Long CTLT (Catalent) or selective mid-cap CDMOs (6–24 months) — thesis: accelerated onshoring of API/finished-dose work and capacity expansion wins. Risk: biotech funding cycles and contract timing. Reward: rerating as utilization rises; consider partial take-profit on +30% move.
• Long DLR (Digital Realty) or EQIX (Equinix) 12–24 months — thesis: lower effective tariffs on heavy electrical and power-grid components reduce capex uncertainty and accelerate data-center builds. Risk: macro slowdown in enterprise spending. Reward: 15–30% upside as leasing and build schedules improve.
• Pair trade: long FCX (Freeport-McMoRan) or SCCO (Southern Copper) vs short an import-dependent OEM like WHR (Whirlpool) over 3–9 months — thesis: commodity/producer capture vs margin squeeze on component-dependent manufacturers. Risk: commodity price reversal or company-specific operational issues. Target: asymmetric 2:1 upside/downside on position sizing.
• Hedge/watch: keep a small options hedge (protective put) on large domestic industrial longs covering the next 60–120 days to guard against legal/retaliation shocks that could reverse tariff benefits quickly.